



**atbtherapeutics launches and raises €1.2M to develop a novel class of therapeutic agent for the field of oncology**

**Belgium, 1 January 2018** – **atbtherapeutics**, a pioneering biopharmaceutical company building a new line of attack for hard-to-treat and refractory cancer using its antibody–toxin–bioengineered **atbody** format, formally announces its launch and the successful closing of its seed financing round, raising over €1.2M.

The **atbody** format is differentiated by both its unique composition and novel mechanism of action, aiming to provide a novel class of biologic. The **atbody** format has been designed to increase the potency, stability, and targeted payload exposure, enlarging the therapeutic window. The resulting biologic holds the potential to evade major cancer cell resistances, enabling treatment of hard-to-treat cancers, thanks to its new mechanism of action. The development of this novel class of biologic agent is driven by the Company's disruptive **atbiofarm** single-step manufacturing technology.

The seed financing was co-led by Financière spin-off, Luxembourgeoise, and Fondation Fournier-Majoie. The company also received financial support from the Région Wallone. **atbtherapeutics** will use the funds primarily to set up its labs and assess the feasibility of its **atbody** format.

**Pierre Detrixhe, atbtherapeutics' Chairman, said:**

“**atbtherapeutics'** disruptive approach has the potential to bring new therapeutic options to the field of oncology. The Company will benefit from fully equipped laboratories and offices in the Novalis Science Park, co-owned by the CERgroup and Idelux. We believe that this engaged entrepreneurial team and collective expertise will enable the company to progress through this next stage of development.”

**Jean-Paul Prieels, Private Investor, added:**

“The potential and challenges of immunoconjugates are well documented. Through pioneering a highly differentiated biologic with a unique composition and a novel mechanism of action, we have here the potential to generate better clinical outcomes, providing a promising therapeutic solution for patients. I am really glad to support the team in this challenge.”

**ENDS**

**For more information please contact**

**atbtherapeutics**  
Dr Bertrand Magy, CEO  
Email: [info@atbtherapeutics.com](mailto:info@atbtherapeutics.com)

**Instinctif Partners**  
Dr Christelle Kerouedan / Siobhan Sanford  
Tel: +44 (0)20 7457 2020  
Email: [atbtherapeutics@instinctif.com](mailto:atbtherapeutics@instinctif.com)

**Notes to Editors**

## About **atb**therapeutics

**atb**therapeutics is a pioneering biopharmaceutical company committed to building a new line of attack for hard-to-treat and refractory cancer.

**atb**therapeutics is developing the antibody-toxin-bioengineered - “**atbody**”: a game-changer format of targeted antibody-based therapy. The **atbody** has been designed to meet the clinical needs presented by hard-to-treat cancer. Its unique composition, avoiding chemical linker issues, has the potential to increase potency, stability and targeted exposure. The differentiated mechanism of action is meant to evade major mechanisms of cancer cell resistance, providing a promising life-changing therapy for cancer.

The **atbody** is enabled by the Company's versatile plant based **atbiofarm** technology. The **atbiofarm** technology leverages plant expression systems in a truly distinct method of production, in a single step manufacturing, avoiding chemical conjugation issues.

**atb**therapeutics is a private company headquartered in Belgium. It was founded in 2018 with seed financing from Financière Spin Off Luxembourgeoise, the Fournier-Majoie Foundation and Noshaq.